Breaking news

AstraZeneca Bolsters Cancer Treatment Capabilities With $1 Billion EsoBiotec Acquisition

The renowned British pharmaceutical company, AstraZeneca, has announced a striking move by acquiring Belgium’s EsoBiotec for an impressive sum of up to $1 billion. This acquisition is expected to significantly boost AstraZeneca’s expertise in cancer treatment formulations.

This ambitious move consists of an immediate payment of $425 million with the potential to invest an additional $575 million to meet developmental and regulatory milestones. This strategic acquisition fully supports AstraZeneca’s vision of revolutionizing cancer treatment through cutting-edge cellular therapy.

EsoBiotec’s platform is renowned for its transformative approach to cellular therapy, aiming to enhance the body’s immune defenses against cancer cells. By engineering immune cells directly within the patient’s body utilizing targeted viruses, what once took weeks for treatment could now potentially be reduced to mere minutes—a groundbreaking leap in medical technology!

Following the conclusion of this deal by the second quarter of 2025, EsoBiotec will operate as a subsidiary under AstraZeneca, continuing its innovative work from Belgium. This move aligns seamlessly with AstraZeneca’s commitment to advancing healthcare and providing innovative solutions in the realm of oncology.

Furthering The Fight Against Cancer

On the same day, AstraZeneca also announced an agreement to license multiple oncology assets from Alteogen. Such strategic partnerships underscore AstraZeneca’s dedication to pioneering advances in cancer treatment.

For more insightful developments such as these, explore the latest Biobank.cy’s Nano-Innovation Sets A New Standard In Targeted Breast Cancer Treatment.

Eurobank Wins Two Euromoney Awards Following Cyprus Merger

Eurobank has been named Cyprus’ Best Bank for 2026 by Euromoney, while also receiving the award for Best Bank for Large Corporates at the publication’s latest Awards for Excellence.

Merger Marks A Milestone

The awards recognise the bank’s performance during 2025, a year marked by the completion of the legal merger between Hellenic Bank and Eurobank Cyprus. The transaction created Eurobank Limited, which the group says is now Cyprus’ largest banking and insurance organisation, with assets exceeding €28 billion.

Euromoney’s Awards for Excellence evaluate banks’ performance over the previous calendar year, with this edition covering January 1 to December 31, 2025.

Lending, Customers And Digital Growth

Eurobank said its business lending portfolio expanded by around 17 per cent during 2025, while its customer base grew to more than 710,000 retail clients and 11,500 business customers.

The bank also continued its digital expansion, saying more than 96 per cent of transactions are now completed through digital channels, and most financing applications are submitted via its mobile app.

Expanding International Presence

Eurobank also highlighted the opening of its first representative office in India, describing the move as a step toward strengthening business links between Cyprus and India while supporting Cyprus’ role as a gateway to the European Union for Indian businesses and investors.

According to the bank, Euromoney recognised not only the successful completion of the merger but also its lending growth, digital transformation and contribution to Cyprus’ position as an international business and investment hub.

CEO On The Awards

“The Euromoney awards confirm Eurobank’s strong momentum and the successful implementation of our group’s strategy in Cyprus,” Chief Executive Michalis Louis said.

He said the merger strengthened the bank’s ability to support households, businesses and the wider economy, while highlighting continued investment in digital services and the opening of the representative office in India as key milestones during the year.

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter